Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002154
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia
Sponsor:
The Dana Foundation
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Parallel Group Placebo-Controlled Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia
Status:
COMPLETED
Status Verified Date:
1996-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl selegiline hydrochloride alone or in combination to HIV-infected patients who have mild to moderate dementia a decline in their mental abilities
Detailed Description:
Patients are randomized to receive thioctic acid alone deprenyl alone thioctic aciddeprenyl or placebo alone for 10 weeks after which all patients may receive active drug on an open-label basis Patients must have seven clinic visits
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 03-D95 | None | None | None |